You have not yet registered? Get your account for free.
Forgot Password? We will send you a reset link
1 November 2022
Ministry of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.222
12 October 2022
Merck and Moderna Announce Exercise of Option by Merck for Joint Development and Commercialization of Investigational Personalized Cancer Vaccine
13 September 2022
Ministry Of Health, Labour and Welfare in Japan Approves Partial Change to a New Drug Authorization for Moderna’s Omicron-Targeting Bivalent Booster COVID-19 Vaccine, mRNA-1273.214
9 September 2022
Moderna Reviews Clinical Trial Programs Across Portfolio at 2022 R&D Day
31 May 2022
Moderna and Takeda Announce Plans to Transfer Marketing Authorization for Spikevax(TM) COVID-19 Vaccine in Japan to Moderna
21 March 2022
Moderna Announces New Supply Agreement for 2023 with Switzerland for Additional Seven Million Doses of Moderna’s COVID-19 Booster Vaccine
